Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Julio Rosenstock, Domenica Rubino, W. Timothy Garvey
Topics & Concepts
SemaglutidePlaceboOverweightMedicineObesityDouble blindRandomized controlled trialPhysical therapyInternal medicineAlternative medicineEndocrinologyDiabetes mellitusType 2 diabetesLiraglutidePathologyDiabetes Treatment and ManagementBariatric Surgery and OutcomesMetabolism, Diabetes, and Cancer